{"prompt": "['2017N330177_04', 'CONFIDENTIAL', '205678', 'Statistical properties of the group sequential design with sample sizes of 65, and 100 per', 'arm are summarized in Table 19.', 'Table 19', 'Probabilities of Crossing Boundaries at the Interim or Final ORR', 'Analysis based on Group Sequential Design', 'Sample', 'Boundaries', 'Cumulative Boundary Crossing', 'Size (per', 'Probabilities', 'Look', 'arm)', '# of Responders', 'Under Ho', 'Under H1', 'Interim (futility)', '25', '<4', '68.21%', '4.96%', 'Final (Efficacy)', '65', '>17', '1.23%', '88.00%', '100', '>24', '0.97%', '93.70%', 'Note: The Cumulative Boundary Crossing Probabilities are calculated based on exact binomial distribution', 'theoretically.', '10.5.9.2. Additional Comparative Futility Stopping Rule Based on Bayesian', 'Approach', 'If both arms pass the futility boundaries based on group sequential design described', 'above, posterior probability of observing a better RR in one arm relative to the other will', 'be calculated. If such a probability is at least 97.5%, then the treatment arm with lower', 'RR will be dropped due to lack of efficacy. This additional guidance was put in to allow', 'for dropping an arm with substantially inferior response rates (e.g. absolute difference', '>', '28%).', 'To calculate the posterior probability, a non-informative Beta prior (0.025, 0.1) will be', 'used for each arm. Details about calculating the posterior probabilities are provided in', 'Appendix 12.', 'Statistical properties for different scenarios based on both futility rules are summarized in', 'Table 20.', 'Table 20', 'Probabilities of Stopping for Futility at the Interim or Claiming', 'Efficacy at the Final ORR Analysis based on Both Futility Rules', 'Futility Stopping', 'Probabilities of', 'Response Rate', 'Boundary Crossing', 'Claiming Efficacy at', 'Scenario', 'Participant', 'Probabilities at IA [1]', 'Final [1]', 'S', 'S per arm', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', '1', '65', '33%', '60%', '53.59%', '0.01%', '44.83%', '99.99%', '2', '65', '33%', '45%', '16.95%', '0.47%', '77.94%', '99.49%', '3 [3]', '65', '33%', '33%', '6.33%', '6.33%', '86.90%', '86.92%', '4', '65', '33%', '25%', '5.09%', '23.83%', '87.89%', '42.39%', '5', '65', '33%', '20%', '4.97%', '44.59%', '87.98%', '12.52%', '6', '65', '33%', '15%', '4.96%', '69.99%', '87.99%', '1.20%', '7', '65', '33%', '10%', '4.96%', '90.85%', '87.99%', '0.01%', '98']['2017N330177_04', 'CONFIDENTIAL', '205678', 'Futility Stopping', 'Probabilities of', 'Response Rate', 'Boundary Crossing', 'Claiming Efficacy at', 'Scenario', 'Participant', 'Probabilities at IA [1]', 'Final [1]', 'S', 'S per arm', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', 'Arm 1 [2]', 'Arm 2 [2]', '8 [4]', '65', '15%', '15%', '68.22%', '68.22%', '1.23%', '1.24%', '9', '100', '33%', '60%', '53.59%', '0.01%', '46.11%', '99.99%', '10', '100', '33%', '45%', '16.95%', '0.47%', '82.09%', '99.53%', '11[3]', '100', '33%', '33%', '6.33%', '6.33%', '92.38%', '92.39%', '12', '100', '33%', '25%', '5.09%', '23.83%', '93.57%', '53.93%', '13', '100', '33%', '20%', '4.97%', '44.59%', '93.68%', '15.46%', '14', '100', '33%', '15%', '4.96%', '69.99%', '93.70%', '0.94%', '15', '100', '33%', '10%', '4.96%', '90.85%', '93.70%', '0.003%', '16 [4]', '100', '15%', '15%', '68.22%', '68.22%', '0.97%', '0.97%', 'Note:', '[1] The Boundary Crossing Probabilities are calculated based on 10,000,000 simulations using R program.', '[2] Arm 1 and Arm 2 in the table just represent two different treatment arms and are not necessarily refers to 3.4', 'mg/kg and 2.5 mg/kg, respectively.', '[3]', 'The power is shown in Scenario 3, and 11 as 86.90% and 92.38% for sample size of 65, and 100 respectively.', '[4] The type I error is shown in Scenario 8, and 16 as 1.23%, and 0.97% for sample size of 65, and 100 respectively.', 'The IA to assess futility will be reviewed by an Independent Data Monitoring Committee', '(IDMC). Additional details of the IA are provided in Section 10.5.9 and will be provided', 'in an IDMC Charter. The stopping rules described above are guidelines for decision-', 'making and the totality of the data will be considered when making a final decision.', 'Participants will continue to be enrolled, dosed, and followed as planned at the time of', 'IA.', '99']\n\n###\n\n", "completion": "END"}